FDA IND Approval Secured
🎉 Breaking News from Trutino Biosciences! 🎉 🚀 FDA IND Approval Secured! 🚀 What happens when a small but mighty start-up dreams big? Magic. The Trutino Team is thrilled to announce our [...]
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Led by Phillip Kim, Ph.D., MBA, Founder and CEO, Trutino Biosciences is a pre-clinical stage [...]
713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model Gallery713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model
713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model
Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines are complex immune mediators which display potent [...]
Abstract 1745: On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models GalleryAbstract 1745: On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models
Abstract 1745: On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models
Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal cell carcinoma. Despite the remarkable and durable [...]
AACR Virtual Annual Meeting, 2021
Session Type: E-Poster Session Session Category: Immunology Session Title: Immunomodulatory Agents and Interventions Presenter: Dr. Emma Langley Permanent Abstract Number: 1745
Boehringer taps Trutino to bag safer, more efficacious cytokines
Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three cytokine therapies. The deal tasks Trutino with applying a platform designed to yield safer, more effective cytokines to [...]